F T Lee, A Rigopoulos, C Hall, K Clarke, S H Cody, F E Smyth, Z Liu, M W Brechbiel, N Hanai, E C Nice, B Catimel, A W Burgess, S Welt, G Ritter, L J Old, A M Scott
The chimeric monoclonal antibody KM871, directed against the G(D3) antigen, is under evaluation for its potential to target melanoma. To facilitate the in vivo evaluation of biodistribution properties and measurement of pharmacokinetics, KM871 was radiolabeled with (125)I via tyrosine residues and with (111)In via the bifunctional metal ion chelator C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid (CHX-A"-DTPA) to lysine residues. Using antigen-positive SK-MEL-28 melanoma cells, immunoreactivities of 42 and 40% cell binding were obtained, respectively, for the two radioconjugates...
June 1, 2001: Cancer Research